Montefiore Einstein

 

Montefiore Einstein
A

Risks, Burdens, Benefits of an Infused Amyloid Monoclonal Antibody Compared to an Oral Cholinesterase Inhibitor

By Montefiore Einstein FEATURING Aviva Cantor, Gary J. Kennedy
By Montefiore Einstein FEATURING Aviva Cantor, Gary J. Kennedy
470 views
April 18, 2024
Disclaimer: On July 2, 2024 the FDA approved Kisunla (donanemab-azbt) injection for the treatment of ...
read more ↘
Comments 0
Login to view comments. Click here to Login
28th Annual Comprehensive Approach to Dementia
21:22

Risks, Burdens, Benefits of an Infused Amyloid Monoclonal Antibody C…

Montefiore Einstein

A. Cantor, G. J. Kennedy

470 views
39:12

Improving Dementia Detection and Management in Primary Care: The 5-C…

Montefiore Einstein

R. Chalmer

432 views
35:27

Insights From the Treatment of Pseudobulbar Palsy for Dementia Care

Montefiore Einstein

D. Antoniello

15 views
10:33

Keep Cognitive and Behavioral Health on the Table in State Master Pl…

Montefiore Einstein

M. B. Friedman

40:04

Home Care Medicaid Update

Montefiore Einstein

R. Arbuco

24 views
16:53

Progress and Challenges: Maintaining the Dementia Voice in Advocacy

Montefiore Einstein

J. A. Levine